Key terms
About SCYX
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SCYX news
Yesterday
12:15pm ET
Buy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal Pipeline
Yesterday
12:10pm ET
Analysts’ Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)
Yesterday
6:48am ET
Buy Recommendation: Scynexis’s Ibrexafungerp Promises Market Breakthrough and Financial Growth
Apr 02
7:02am ET
Scynexis price target lowered to $6 from $7 at Guggenheim
Apr 02
6:46am ET
Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership
Mar 28
4:08pm ET
Scynexis reports FY23 EPS $1.39, consensus $1.42
SCYX Financials
Key terms
Ad Feedback
SCYX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SCYX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range